AstraZeneca PLC’s Imfinzi (durvalumab) could be poised for expanded use in the big first-line metastatic non-small cell lung cancer market now that, at long last, a trial testing the PD-L1 inhibitor with AstraZeneca’s CTLA-4 antibody tremelimumab in first-line NSCLC met the primary endpoint of improvement in progression-free survival.
POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed
Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.
More from Anticancer
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.